NCT00672022View on ClinicalTrials.gov

Pharmacokinetics, Safety and Tolerability of Zavesca (Miglustat) in Patients With Infantile Onset Gangliosidosis: Single and Steady State Oral Doses

PHASE3CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

July 31, 2004

Primary Completion Date

August 31, 2007

Study Completion Date

August 31, 2007

Conditions
GM2 GangliosidosesTay-SachsSandhoff Disease
Interventions
DRUG

Zavesca (Miglustat)

Trial Locations (1)

20010

Children's National Medical Center, Washington D.C.

Sponsors

Collaborators (1)

Actelion
All Listed Sponsors
collaborator

Actelion

INDUSTRY

lead

Children's National Research Institute

OTHER

NCT00672022 - Pharmacokinetics, Safety and Tolerability of Zavesca (Miglustat) in Patients With Infantile Onset Gangliosidosis: Single and Steady State Oral Doses | Biotech Hunter | Biotech Hunter